ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’

• Combined revenue from IBSRELA and XPHOZAH, the company’s two flagship commercial products, is on track to exceed $500 million this year.
• The company also reaffirmed its $1 billion IBSRELA target by 2029 and $750 million peak for XPHOZAH.
• Ardelyx’s late-stage trial of IBSRELA in Chronic Idiopathic Constipation is progressing on schedule, the company said.

Ardelyx Inc. (ARDX) shares climbed about 2% in after-hours trading on Wednesday after the firm reiterated its 2026 guidance for its blockbuster drug IBSRELA and assured that profitability is “right around the corner.”

CFO Sue Hohenleitner and Chief Commercial Officer Eric Foster spoke at the Jefferies Global Healthcare Conference and confirmed that combined revenue from IBSRELA and XPHOZAH, the company’s two flagship commercial products, is on track to exceed $500 million this year. IBSRELA is guided to $410–430 million, while XPHOZAH is expected at $110–120 million. The company reaffirmed its $1 billion IBSRELA target by 2029 and $750 million peak for XPHOZAH.

While IBSRELA is approved for the treatment of irritable bowel syndrome with constipation, XPHOZAH is approved to reduce serum phosphorus levels in adults with chronic kidney disease on dialysis.

Outlining Priorities

Hohenleitner outlined the four 2026 priorities: growing IBSRELA demand, maintaining XPHOZAH momentum, advancing the pipeline, and delivering strong financial performance. Operating expenses are guided at up to $520 million, a roughly 25% increase driven by sales expansion and patient-activation programs.

Key growth drivers include expanding the sales force from 124 to 144 reps, pushing more prescriptions through the specialty pharmacy network, and targeted patient engagement via social media and streaming TV.

“We know when those prescriptions go to the IBSRELA Pharmacy Network, there’s a higher fulfillment rate as well as, on average, one more refill on an annual basis,” Foster said.

Pipeline And Profitability

On the pipeline, the company said that its late-stage trial of IBSRELA in Chronic Idiopathic Constipation is progressing on schedule, with full enrollment expected by year-end and top-line data in mid-2027.

Hohenleitner also said profitability is “right around the corner,” though the company is waiting for more top-line certainty before formal guidance.

How Did ARDX Retail Traders React?

On Stocktwits, retail sentiment around ARDX stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels

A Stocktwits user hinted that ARDX is an undervalued company.

Another highlighted the company’s strong revenue growth in the first quarter.

According to data from Koyfin, all ten of the ten analysts covering ARDX rate it 'Buy' or higher. The 12-month average price target on the stock is $16.33, representing a potential upside of over 200% from the last close.

ARDX stock has gained 38% over the past 12 months. 

Read More: RIVN Stock Eyes 10th Straight Day Of Gains — CFO Teases More Licensing Deals Ahead Of R2 Deliveries

For updates and corrections, email newsroom[at]stocktwits[dot]com.